Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARLAN HARVEY

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1902035066
CMS profile
702573
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$411,390.00

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $411,390.00 140

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $389,670.00 127
PFIZER INC. $21,720.00 13

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARLAN HARVEY

NPI 1902035066 · CMS profile ID 702573

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902035066?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARLAN HARVEY, NPI 1902035066, CMS profile ID 702573. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902035066?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HARLAN HARVEY, NPI 1902035066, CMS profile ID 702573. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902035066?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HARLAN HARVEY, NPI 1902035066, CMS profile ID 702573, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1902035066?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $411,390.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–140 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $60.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848390723 CMS
Merck Sharp & Dohme Corporation $2,430.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848489113 CMS
Merck Sharp & Dohme Corporation $2,580.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848489115 CMS
Merck Sharp & Dohme Corporation $540.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848499297 CMS
Merck Sharp & Dohme Corporation $360.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848499299 CMS
Merck Sharp & Dohme Corporation $6,540.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848557165 CMS
Merck Sharp & Dohme Corporation $1,800.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848595309 CMS
Merck Sharp & Dohme Corporation $3,960.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848647583 CMS
Merck Sharp & Dohme Corporation $480.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848683603 CMS
Merck Sharp & Dohme LLC $990.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848729175 CMS
PFIZER INC. $4,125.0003/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832829981 CMS
Merck Sharp & Dohme Corporation $600.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848391403 CMS
Merck Sharp & Dohme Corporation $6,420.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848557163 CMS
Merck Sharp & Dohme Corporation $2,940.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848581319 CMS
Merck Sharp & Dohme Corporation $990.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848581321 CMS
Merck Sharp & Dohme Corporation $960.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848595433 CMS
Merck Sharp & Dohme Corporation $480.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848618069 CMS
Merck Sharp & Dohme Corporation $1,800.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848729071 CMS
Merck Sharp & Dohme LLC $1,710.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848469315 CMS
Merck Sharp & Dohme LLC $150.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848475017 CMS
PFIZER INC. $645.0003/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832829971 CMS
Merck Sharp & Dohme Corporation $2,160.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848390721 CMS
Merck Sharp & Dohme Corporation $240.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848390725 CMS
Merck Sharp & Dohme Corporation $480.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848447199 CMS
Merck Sharp & Dohme Corporation $8,760.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848489245 CMS
Merck Sharp & Dohme Corporation $1,980.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848581317 CMS
Merck Sharp & Dohme Corporation $1,440.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848624759 CMS
Merck Sharp & Dohme Corporation $2,940.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848637111 CMS
Merck Sharp & Dohme Corporation $3,720.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848705793 CMS
Merck Sharp & Dohme LLC $1,890.0002/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848475019 CMS
PFIZER INC. $755.0001/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832829563 CMS
Merck Sharp & Dohme Corporation $4,590.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848499301 CMS
Merck Sharp & Dohme Corporation $3,720.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848530301 CMS
Merck Sharp & Dohme Corporation $2,820.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848557161 CMS
Merck Sharp & Dohme Corporation $150.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848595307 CMS
Merck Sharp & Dohme Corporation $840.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848595431 CMS
Merck Sharp & Dohme Corporation $1,740.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848595435 CMS
Merck Sharp & Dohme Corporation $180.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848637107 CMS
Merck Sharp & Dohme Corporation $2,970.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848729073 CMS
Merck Sharp & Dohme LLC $4,050.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848683601 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,930.70 4
PY2020 $128,245.00 51
PY2021 $411,390.00 140
PY2022 $16,760.00 5
PY2023 $23,635.00 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $117,862.10 22
PY2025 Principal investigator $12,790.00 2
PY2024 Recipient $71,319.00 7
PY2024 Principal investigator $1,390.46 4
PY2023 Recipient $156,915.00 5
PY2023 Principal investigator $95,324.00 42
PY2022 Recipient $73,365.00 5
PY2022 Principal investigator $138,420.00 27
PY2021 Recipient $23,310.00 2
PY2021 Principal investigator $51,175.00 29
PY2020 Principal investigator $96,410.00 22
PY2019 Principal investigator $25,640.00 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,410.00 11/25/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202525256
Recipient GlaxoSmithKline, LLC. $8,700.00 10/15/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192134513
Recipient GlaxoSmithKline, LLC. $4,409.61 10/15/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192134550
Recipient GlaxoSmithKline, LLC. $1,925.00 09/16/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192139944
Recipient GlaxoSmithKline, LLC. $3,521.69 09/16/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192139963
Principal investigator 1 AstraZeneca UK Limited $5,380.00 08/12/2025 Non-covered Recipient Entity
VALUE BASED CONSULTANT LLC
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185546541
Recipient GlaxoSmithKline, LLC. $460.58 08/10/2025 Covered Recipient Physician A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192139950
Recipient GlaxoSmithKline, LLC. $6,710.17 08/10/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192139980
Recipient GlaxoSmithKline, LLC. $11,098.57 07/15/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192134573
Recipient GlaxoSmithKline, LLC. $3,629.67 07/15/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192139970
Recipient GlaxoSmithKline, LLC. $2,259.23 06/11/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192134533
Recipient GlaxoSmithKline, LLC. $7,475.00 06/11/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192134539
Recipient GlaxoSmithKline, LLC. $11,025.00 05/13/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192134525
Recipient GlaxoSmithKline, LLC. $2,157.86 05/13/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192139976
Recipient GlaxoSmithKline, LLC. $3,848.24 04/15/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192134519
Recipient GlaxoSmithKline, LLC. $6,100.00 04/15/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192134566
Recipient GlaxoSmithKline, LLC. $3,040.27 03/13/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192134560
Recipient GlaxoSmithKline, LLC. $13,518.43 03/13/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192139987
Recipient GlaxoSmithKline, LLC. $7,900.00 02/12/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192139937
Recipient GlaxoSmithKline, LLC. $2,324.21 02/12/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192139957
Recipient GlaxoSmithKline, LLC. $9,361.00 01/15/2025 Covered Recipient Physician A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTO No dispute reported 06/30/2026 1192134543
Recipient GlaxoSmithKline, LLC. $1,932.57 01/15/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192134555
Recipient Eli Lilly and Company $2,970.00 01/03/2025 Covered Recipient Physician A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1187870981
Recipient Eli Lilly and Company $3,495.00 01/03/2025 Covered Recipient Physician A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) No dispute reported 06/30/2026 1187872411